Prevalence, Medicaid use and mortality risk of low FEV


Journal

BMJ open respiratory research
ISSN: 2052-4439
Titre abrégé: BMJ Open Respir Res
Pays: England
ID NLM: 101638061

Informations de publication

Date de publication:
15 May 2024
Historique:
received: 27 06 2023
accepted: 19 04 2024
medline: 16 5 2024
pubmed: 16 5 2024
entrez: 15 5 2024
Statut: epublish

Résumé

The prevalence, Medicaid use and mortality risk associated with low forced expiratory volume in 1 s (FEV A retrospective cohort study was conducted among young adults aged 20-35 years old, using data from the National Health and Nutrition Examination Survey, National Death Index and Centers for Medicare & Medicaid Services. Participants were categorised into a low FEV A total of 5346 participants aged 20-35 were included in the study, with 329 in the low FEV A considerable portion of young adults demonstrated low FEV

Sections du résumé

BACKGROUND BACKGROUND
The prevalence, Medicaid use and mortality risk associated with low forced expiratory volume in 1 s (FEV
METHODS METHODS
A retrospective cohort study was conducted among young adults aged 20-35 years old, using data from the National Health and Nutrition Examination Survey, National Death Index and Centers for Medicare & Medicaid Services. Participants were categorised into a low FEV
RESULTS RESULTS
A total of 5346 participants aged 20-35 were included in the study, with 329 in the low FEV
CONCLUSIONS CONCLUSIONS
A considerable portion of young adults demonstrated low FEV

Identifiants

pubmed: 38749533
pii: 11/1/e001918
doi: 10.1136/bmjresp-2023-001918
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Zihui Wang (Z)

Guangzhou Institute of Respiratory Disease, Guangzhou, Guangdong, China.
First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.

Yun Li (Y)

Guangzhou Institute of Respiratory Disease, Guangzhou, Guangdong, China.
First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.

Lunfang Tan (L)

Guangzhou Institute of Respiratory Disease, Guangzhou, Guangdong, China.
First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.

Shuyi Liu (S)

Guangzhou Institute of Respiratory Disease, Guangzhou, Guangdong, China.
First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.

Zhufeng Wang (Z)

Guangzhou Institute of Respiratory Disease, Guangzhou, Guangdong, China.
First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.

Qing Zhang (Q)

Guangzhou Institute of Respiratory Disease, Guangzhou, Guangdong, China.
First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.

Junfeng Lin (J)

Guangzhou Institute of Respiratory Disease, Guangzhou, Guangdong, China.
First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.

Jinhai Huang (J)

Guangzhou Institute of Respiratory Disease, Guangzhou, Guangdong, China.
First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.

Lina Liang (L)

Guangzhou Institute of Respiratory Disease, Guangzhou, Guangdong, China.
First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.

Yi Gao (Y)

Guangzhou Institute of Respiratory Disease, Guangzhou, Guangdong, China.
First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.

Nanshan Zhong (N)

Guangzhou Institute of Respiratory Disease, Guangzhou, Guangdong, China.
First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.

Jinping Zheng (J)

Guangzhou Institute of Respiratory Disease, Guangzhou, Guangdong, China jpzhenggy@163.com.
First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH